Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers

Histopathology

Volumn 59, Issue 3, 2011, Pages 482-495

  Zlobec, Inti ^a   Minoo, Parham ^b   Terracciano, Luigi ^a   Baker, Kristi ^c   Lugli, Alessandro ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

CD68; CD8; Colorectal cancer; FoxP3; Prognosis; Tumour budding

Indexed keywords

CD16 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CYTOKERATIN; CYTOKERATIN 22; GRANZYME B; LYMPHOCYTE ANTIGEN; SYNDECAN 1; T CELL INTRACELLULAR ANTIGEN 1; TRANSCRIPTION FACTOR FOXP3; TRYPTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; MISMATCH REPAIR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR BUD; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; T-LYMPHOCYTE SUBSETS; TUMOR MICROENVIRONMENT;

EID: 80053320027     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03975.x     Document Type: Article

References (52)

1. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009; 119; 1420-1428.
2. Brabletz T, Hlubek F, Spaderna S et al. Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs 2005; 179; 56-65.
3. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007; 50; 151-162.
4. Ueno H, Mochizuki H, Hashiguchi Y, Hatsuse K, Fujimoto H, Hase K. Predictors of extrahepatic recurrence after resection of colorectal liver metastases. Br. J. Surg. 2004; 91; 327-333.
5. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002; 40; 127-132.
6. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88; 1739-1757.
7. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J. Clin. Pathol. 1986; 39; 585-589.
8. Zlobec I, Lugli A, Baker K et al. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer. J. Pathol. 2007; 212; 260-268.
9. Shinto E, Mochizuki H, Ueno H, Matsubara O, Jass JR. A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci. Histopathology 2005; 47; 25-31.
10. Jass J. Tumor budding in colorectal cancer, Chapter 5. New York: Nova Science Publishers, 2006; 77-83.
11. Lugli A, Karamitopoulou E, Panayiotides I et al. CD8+ lymphocytes/tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer. Br. J. Cancer 2009; 101; 1382-1392.
12. Shinto E, Jass JR, Tsuda H et al. Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis. Colon Rectum 2006; 49; 1422-1430.
13. Baker K, Zlobec I, Tornillo L, Terracciano L, Jass JR, Lugli A. Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. Eur. J. Cancer 2007; 43; 624-631.
14. Galon J, Costes A, Sanchez-Cabo F et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313; 1960-1964.
15. Salama P, Phillips M, Grieu F et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 2009; 27; 186-192.
16. Milasiene V, Stratilatovas E, Norkiene V, Jonusauskaite R. Lymphocyte subsets in peripheral blood as prognostic factors in colorectal cancer. J. Buon. 2005; 10; 261-264.
17. Rafique M, Adachi W, Koike S et al. Adverse effects of intraportal chemotherapy on natural killer cell activity in colorectal cancer patients. J. Surg. Oncol. 1997; 64; 324-330.
18. Blatner NR, Bonertz A, Beckhove P et al. In colorectal cancer mast cells contribute to systemic regulatory T-cell dysfunction. Proc. Natl Acad. Sci. USA 2010; 107; 6430-6435.
19. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin. Cancer Res. 2007; 13; 1472-1479.
20. Milne K, Kobel M, Kalloger SE et al. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009; 4; e6412.
21. Sandel MH, Dadabayev AR, Menon AG et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin. Cancer Res. 2005; 11; 2576-2582.
22. Lugli A, Zlobec I, Minoo P et al. Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal-regulated kinase, and phosphorylated AKT in colorectal cancer-a tissue microarray-based approach. Hum. Pathol. 2006; 37; 1022-1031.
23. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998; 316; 1236-1238.
24. Hori H, Fujimori T, Fujii S et al. Evaluation of tumor cell dissociation as a predictive marker of lymph node metastasis in submucosal invasive colorectal carcinoma. Dis. Colon Rectum 2005; 48; 938-945.
25. Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K. Evaluation of the usefulness of tumor budding on the prediction of metastasis to the lung and liver after curative excision of colorectal cancer. Hepatogastroenterology 2005; 52; 1432-1435.
26. Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology 2005; 47; 17-24.
27. Prall F, Ostwald C. High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations. Hum. Pathol. 2007; 38; 1696-1702.
28. Ueno H, Mochizuki H, Hashiguchi Y et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127; 385-394.
29. Brabletz T. Tumor budding in colorectal cancer, Chapter 4. New York: Nova Science Publishers, Inc., 2006; 49-70.
30. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005; 5; 744-749.
31. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumor 'budding' in patients with colorectal cancer. Dis. Colon Rectum 1993; 36; 627-635.
32. Wang LM, Kevans D, Mulcahy H et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am. J. Surg. Pathol. 2009; 33; 134-141.
33. Csiba A, Whitwell HL, Moore M. Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonic neoplasms. Br. J. Cancer 1984; 50; 699-709.
34. Umpleby HC, Heinemann D, Symes MO, Williamson RC. Expression of histocompatibility antigens and characterization of mononuclear cell infiltrates in normal and neoplastic colorectal tissues of humans. J. Natl Cancer Inst. 1985; 74; 1161-1168.
35. Michael-Robinson JM, Biemer-Huttmann A, Purdie DM et al. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 2001; 48; 360-366.
36. Naito Y, Saito K, Shiiba K et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58; 3491-3494.
37. Menon AG, Janssen-van Rhijn CM, Morreau H et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab. Invest. 2004; 84; 493-501.
38. Ohtani H, Naito Y, Saito K, Nagura H. Expression of costimulatory molecules B7-1 and B7-2 by macrophages along invasive margin of colon cancer: a possible antitumor immunity? Lab. Invest. 1997; 77; 231-241.
39. Khazaie K, von Boehmer H. The impact of CD4+CD25+ Treg on tumor specific CD8+ T cell cytotoxicity and cancer. Semin. Cancer Biol. 2006; 16; 124-136.
40. Watson NF, Ramage JM, Madjd Z et al. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int. J. Cancer 2006; 118; 6-10.
41. Feuerer M, Hill JA, Mathis D, Benoist C. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat. Immunol. 2009; 10; 689-695.
42. Le Gouvello S, Bastuji-Garin S, Aloulou N et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008; 57; 772-779.
43. Chaput N, Louafi S, Bardier A et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 2009; 58; 520-529.
44. de Kruijf EM, van Nes JG, Sajet A et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin. Cancer Res. 2010; 16; 1272-1280.
45. Carroll RP, Segundo DS, Hollowood K et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J. Am. Soc. Nephrol. 2010; 21; 713-722.
46. Sasaki A, Tanaka F, Mimori K et al. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur. J. Surg. Oncol. 2008; 34; 173-179.
47. Frey DM, Droese RA, Viehl CT et al. High frequency of tumor-infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int. J. Cancer 2010; 126; 2635-2643.
48. Suzuki H, Chikazawa N, Tasaka T et al. Intratumoral CD8(+) T/FOXP3 (+) cell ratio is a predictive marker for survival in patients with colorectal cancer. Cancer Immunol. Immunother. 2010; 59; 653-661.
49. Heinze E, Baldwin S, Chan G et al. Antibody-mediated FOXP3 protein therapy induces apoptosis in cancer cells in vitro and inhibits metastasis in vivo. Int. J. Oncol. 2009; 35; 167-173.
50. Compton C. AJCC Cancer Staging Manual, Chapter 14. New York, NY: Springer, 2010; 143-164.
51. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
52. Stark JR, Perner S, Stampfer MJ et al. Gleason score and lethal prostate cancer: does 3+4=4+3? J. Clin. Oncol. 2009; 27; 3459-3464.